Prices delayed by at least 15 minutes | Print
Johnson & Johnson (JNJ)
Common StockOpen
$145
Previous close
$144.45
Trade high
$145.41
Volume
9,378,059
Year high
$175.97
Year low
$143.39
Dividend yield
3.3%
Market capitalisation
$348.86 bn
P/E ratio
27.78
ISIN
US4781601046
This share can be held in a Dealing accountISALifetime ISAJISASIPP
Share price
Dividends
Previous | Latest | |
---|---|---|
Record date | 20/02/2024 | 21/05/2024 |
Ex-dividend date | 16/02/2024 | 20/05/2024 |
Payment date | 05/03/2024 | 04/06/2024 |
Amount | $1.19 | $1.24 |
Company profile
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.